Today's Stocks Driving Success For The Health Care Sector

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

All three major indices are trading up today with the Dow Jones Industrial Average ( ^DJI) trading up 156 points (1.0%) at 15,978 as of Friday, Dec. 6, 2013, 11:45 AM ET. The NYSE advances/declines ratio sits at 2,203 issues advancing vs. 732 declining with 103 unchanged.

The Health Care sector currently sits up 0.5% versus the S&P 500, which is up 0.9%. Top gainers within the sector include Boston Scientific ( BSX), up 4.2%, Cigna ( CI), up 2.5%, Intuitive Surgical ( ISRG), up 2.2%, Thermo Fisher Scientific ( TMO), up 2.0% and Agilent Technologies ( A), up 2.0%. A company within the sector that fell today was Teva Pharmaceutical Industries ( TEVA), up 0.6%.

TheStreet would like to highlight 5 stocks pushing the sector higher today:

5. Biogen Idec ( BIIB) is one of the companies pushing the Health Care sector higher today. As of noon trading, Biogen Idec is up $7.20 (2.5%) to $292.12 on average volume. Thus far, 465,121 shares of Biogen Idec exchanged hands as compared to its average daily volume of 1.2 million shares. The stock has ranged in price between $283.00-$292.49 after having opened the day at $289.55 as compared to the previous trading day's close of $284.92.

Biogen Idec Inc. discovers, develops, manufactures, and markets therapies for the treatment of neurodegenerative diseases, hemophilia, and autoimmune disorders in the United States and internationally. Biogen Idec has a market cap of $67.5 billion and is part of the drugs industry. The company has a P/E ratio of 40.1, above the S&P 500 P/E ratio of 17.7. Shares are up 95.3% year to date as of the close of trading on Thursday. Currently there are 14 analysts that rate Biogen Idec a buy, no analysts rate it a sell, and 5 rate it a hold.

TheStreet Ratings rates Biogen Idec as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures, notable return on equity, reasonable valuation levels and solid stock price performance. Although the company may harbor some minor weaknesses, we feel they are unlikely to have a significant impact on results. Get the full Biogen Idec Ratings Report now.

3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

4. As of noon trading, Gilead ( GILD) is up $0.80 (1.1%) to $73.99 on average volume. Thus far, 4.0 million shares of Gilead exchanged hands as compared to its average daily volume of 8.9 million shares. The stock has ranged in price between $73.08-$74.11 after having opened the day at $74.06 as compared to the previous trading day's close of $73.19.

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes human therapeutics for the treatment of life threatening diseases in North America, Europe, and Asia. Gilead has a market cap of $111.1 billion and is part of the drugs industry. The company has a P/E ratio of 39.8, above the S&P 500 P/E ratio of 17.7. Shares are up 99.3% year to date as of the close of trading on Thursday. Currently there are 16 analysts that rate Gilead a buy, no analysts rate it a sell, and 2 rate it a hold.

TheStreet Ratings rates Gilead as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, solid stock price performance, reasonable valuation levels, expanding profit margins and good cash flow from operations. Although no company is perfect, currently we do not see any significant weaknesses which are likely to detract from the generally positive outlook. Get the full Gilead Ratings Report now.

3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

3. As of noon trading, Johnson & Johnson ( JNJ) is up $0.92 (1.0%) to $93.89 on light volume. Thus far, 2.3 million shares of Johnson & Johnson exchanged hands as compared to its average daily volume of 7.3 million shares. The stock has ranged in price between $93.42-$94.04 after having opened the day at $93.57 as compared to the previous trading day's close of $92.97.

Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of various products in the health care field worldwide. The company operates in three segments: Consumer, Pharmaceutical, and Medical Devices and Diagnostics. Johnson & Johnson has a market cap of $264.2 billion and is part of the drugs industry. The company has a P/E ratio of 20.9, above the S&P 500 P/E ratio of 17.7. Shares are up 32.6% year to date as of the close of trading on Thursday. Currently there are 8 analysts that rate Johnson & Johnson a buy, no analysts rate it a sell, and 8 rate it a hold.

TheStreet Ratings rates Johnson & Johnson as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, solid stock price performance, reasonable valuation levels and good cash flow from operations. Although no company is perfect, currently we do not see any significant weaknesses which are likely to detract from the generally positive outlook. Get the full Johnson & Johnson Ratings Report now.

3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

2. As of noon trading, Merck ( MRK) is up $0.53 (1.1%) to $49.34 on light volume. Thus far, 2.5 million shares of Merck exchanged hands as compared to its average daily volume of 14.3 million shares. The stock has ranged in price between $48.96-$49.36 after having opened the day at $49.13 as compared to the previous trading day's close of $48.81.

Merck & Co., Inc. provides various health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products worldwide. Merck has a market cap of $144.1 billion and is part of the drugs industry. The company has a P/E ratio of 33.1, above the S&P 500 P/E ratio of 17.7. Shares are up 19.2% year to date as of the close of trading on Thursday. Currently there are 5 analysts that rate Merck a buy, 1 analyst rates it a sell, and 8 rate it a hold.

TheStreet Ratings rates Merck as a buy. The company's strengths can be seen in multiple areas, such as its largely solid financial position with reasonable debt levels by most measures, good cash flow from operations, expanding profit margins and increase in stock price during the past year. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full Merck Ratings Report now.

3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

1. As of noon trading, Pfizer ( PFE) is up $0.21 (0.7%) to $31.46 on light volume. Thus far, 6.3 million shares of Pfizer exchanged hands as compared to its average daily volume of 25.5 million shares. The stock has ranged in price between $31.32-$31.61 after having opened the day at $31.55 as compared to the previous trading day's close of $31.25.

Pfizer Inc., a biopharmaceutical company, discovers, develops, manufactures, and sells medicines for people and animals worldwide. Pfizer has a market cap of $202.7 billion and is part of the drugs industry. The company has a P/E ratio of 20.7, above the S&P 500 P/E ratio of 17.7. Shares are up 24.6% year to date as of the close of trading on Thursday. Currently there are 8 analysts that rate Pfizer a buy, 1 analyst rates it a sell, and 3 rate it a hold.

TheStreet Ratings rates Pfizer as a buy. The company's strengths can be seen in multiple areas, such as its largely solid financial position with reasonable debt levels by most measures, reasonable valuation levels, solid stock price performance, good cash flow from operations and expanding profit margins. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full Pfizer Ratings Report now.

3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

If you are interested in one of these 5 stocks, ETFs may be of interest. Investors who are bullish on the health care sector could consider Health Care Select Sector SPDR ( XLV) while those bearish on the health care sector could consider ProShares Ultra Short Health Care ( RXD).
null